From the ∗Department of Medicine, University of Washington
†Public Health—Seattle & King County, HIV/STD Program
‡Departments of Epidemiology
§Global Health, University of Washington, Seattle, WA
Conflict of Interest and Sources of Funding: L.A.B. has received research support from Hologic, SpeeDx, and Nabriva, unrelated to the current work. O.O.S. and M.R.G. have received research support from SpeeDx and Hologic, unrelated to the current work. S.E.M., A.B., and C.S.T. have none to declare.
Funding provided by the National Institutes of Health: T32 AI007140-43 and by funding from the US Centers for Disease Control and Prevention's Epidemiology and Laboratory Capacity for the Prevention and Control of Infectious Diseases Cooperative Agreement (CK19-1904) under the Strengthening the US Response to Resistant Gonorrhea project.
Correspondence: Stephanie E. McLaughlin, MD, MPH, Division of Allergy and Infectious Diseases, University of Washington, Harborview Medical Center, Box 359777, 325 9th Ave, Seattle, WA 98104. E-mail: [email protected]; Lindley A. Barbee, MD, MPH, 325 9th Ave, Box 359777, Seattle, WA 98104. E-mail: [email protected].
Received for publication May 29, 2022, and accepted December 14, 2022.
